AMPH RSI Chart
Last 7 days
3.0%
Last 30 days
8.6%
Last 90 days
-19.6%
Trailing 12 Months
-0.8%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 676.2M | 0 | 0 | 0 |
2023 | 518.6M | 540.9M | 601.3M | 644.4M |
2022 | 455.1M | 476.9M | 484.9M | 499.0M |
2021 | 368.2M | 384.0M | 412.8M | 437.8M |
2020 | 327.3M | 334.0M | 337.3M | 349.8M |
2019 | 316.1M | 324.1M | 328.7M | 322.4M |
2018 | 241.9M | 247.8M | 265.4M | 294.7M |
2017 | 252.5M | 249.6M | 243.3M | 240.2M |
2016 | 254.0M | 268.2M | 268.5M | 255.2M |
2015 | 221.5M | 226.3M | 230.5M | 251.5M |
2014 | 222.6M | 209.1M | 209.5M | 210.5M |
2013 | 210.7M | 217.0M | 223.3M | 229.7M |
2012 | 0 | 0 | 0 | 204.3M |
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index
Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>
Returns of $10,000 invested in:
Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224
Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
May 01, 2024 | petersen floyd f. | sold | -20,836 | 41.6739 | -500 | - |
Apr 01, 2024 | petersen floyd f. | sold | -21,714 | 43.4283 | -500 | - |
Mar 17, 2024 | zhou rong | sold (taxes) | -84,421 | 43.05 | -1,961 | senior evp, production center |
Mar 17, 2024 | zhang jack y. | sold (taxes) | -303,589 | 43.05 | -7,052 | ceo & chief scientific officer |
Mar 17, 2024 | zhang jack y. | sold (taxes) | -678,812 | 43.05 | -15,768 | ceo & chief scientific officer |
Mar 17, 2024 | liawatidewi yakob | sold (taxes) | -74,304 | 43.05 | -1,726 | evp corp admin center |
Mar 17, 2024 | peters william j | sold (taxes) | -183,178 | 43.05 | -4,255 | cfo, evp & treasurer |
Mar 16, 2024 | peters william j | sold (taxes) | -219,770 | 43.05 | -5,105 | cfo, evp & treasurer |
Mar 16, 2024 | liawatidewi yakob | sold (taxes) | -71,936 | 43.05 | -1,671 | evp corp admin center |
Mar 16, 2024 | zhou rong | sold (taxes) | -101,383 | 43.05 | -2,355 | senior evp, production center |
Which funds bought or sold AMPH recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 17, 2024 | VIMA LLC | sold off | -100 | -17,936 | - | -% |
May 16, 2024 | HANCOCK WHITNEY CORP | added | 58.42 | 29,727 | 268,160 | 0.01% |
May 16, 2024 | B. Riley Wealth Advisors, Inc. | sold off | -100 | -409,942 | - | -% |
May 16, 2024 | Virtus Investment Advisers, Inc. | unchanged | - | -109,596 | 268,246 | 0.19% |
May 16, 2024 | JANE STREET GROUP, LLC | reduced | -25.24 | -1,508,560 | 1,706,340 | -% |
May 16, 2024 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -7.01 | -865,045 | 1,680,390 | -% |
May 16, 2024 | COMERICA BANK | reduced | -7.03 | -352,623 | 684,601 | -% |
May 15, 2024 | Clark Capital Management Group, Inc. | reduced | -35.63 | -2,090,460 | 1,759,210 | 0.01% |
May 15, 2024 | Point72 (DIFC) Ltd | new | - | 462,504 | 462,504 | 0.01% |
May 15, 2024 | CAROLINAS WEALTH CONSULTING LLC | unchanged | - | -587 | 1,437 | -% |
Unveiling Amphastar Pharmaceuticals Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Amphastar Pharmaceuticals Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 372.2B | 85.6B | 9.67 | 4.35 | ||||
MRK | 332.3B | 61.4B | 144.1 | 5.41 | ||||
AMGN | 167.7B | 29.5B | 44.55 | 5.68 | ||||
PFE | 162.3B | 57.8B | 129.52 | 2.81 | ||||
GILD | 84.4B | 27.4B | 174.21 | 3.07 | ||||
TEVA | 18.4B | 16.0B | -37.29 | 1.15 | ||||
MID-CAP | ||||||||
ALKS | 4.1B | 1.7B | 9.41 | 2.37 | ||||
PRGO | 4.1B | 4.6B | -528.11 | 0.89 | ||||
BHC | 2.5B | 9.0B | -5.45 | 0.28 | ||||
AMPH | 2.1B | 676.2M | 13.75 | 3.14 | ||||
SMALL-CAP | ||||||||
TLRY | 1.5B | 743.2M | -4.35 | 2.06 | ||||
TXMD | 25.8M | 1.3M | -3.49 | 19.84 | ||||
ACRX | 18.4M | 89.6M | -1.29 | 0.19 | ||||
AGRX | 2.5M | 21.5M | -0.32 | 0.12 | ||||
ACOR | 633.5K | 115.7M | 0 | 0.01 |
Amphastar Pharmaceuticals Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | -3.5% | 172 | 178 | 181 | 146 | 140 | 135 | 120 | 123 | 120 | 121 | 112 | 102 | 103 | 96.00 | 83.00 | 86.00 | 85.00 | 83.00 | 80.00 | 79.00 | 80.00 |
Cost Of Revenue | -0.3% | 82.00 | 82.00 | 72.00 | 73.00 | 66.00 | 64.00 | 62.00 | 60.00 | 65.00 | 65.00 | 61.00 | 54.00 | 58.00 | 59.00 | 47.00 | 53.00 | 48.00 | 50.00 | 45.00 | 47.00 | 49.00 |
Gross Profit | -6.3% | 90.00 | 96.00 | 108 | 73.00 | 74.00 | 71.00 | 59.00 | 63.00 | 56.00 | 56.00 | 51.00 | 47.00 | 45.00 | 37.00 | 37.00 | 33.00 | 37.00 | 33.00 | 35.00 | 32.00 | 31.00 |
Operating Expenses | -0.2% | 42.00 | 42.00 | 36.00 | 36.00 | 40.00 | 33.00 | 35.00 | 39.00 | 34.00 | 32.00 | 26.00 | 37.00 | 35.00 | 34.00 | 33.00 | 36.00 | 29.00 | 34.00 | 33.00 | 31.00 | 34.00 |
S&GA Expenses | 8.7% | 9.00 | 9.00 | 6.00 | 7.00 | 7.00 | 5.00 | 5.00 | 6.00 | 6.00 | 4.00 | 5.00 | 4.00 | 5.00 | 4.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
R&D Expenses | -16.5% | 17.00 | 20.00 | 17.00 | 17.00 | 20.00 | 17.00 | 19.00 | 23.00 | 16.00 | 17.00 | 11.00 | 18.00 | 15.00 | 18.00 | 18.00 | 16.00 | 15.00 | 20.00 | 19.00 | 16.00 | 15.00 |
EBITDA Margin | 4.9% | 0.36* | 0.35* | 0.36* | 0.30* | 0.28* | 0.28* | 0.26* | 0.29* | 0.29* | 0.24* | 0.18* | 0.11* | - | - | - | - | - | - | - | - | - |
Interest Expenses | -8.9% | 9.00 | 9.00 | 14.00 | 4.00 | 0.00 | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income Taxes | -11.7% | 4.00 | 5.00 | 14.00 | 6.00 | 7.00 | 7.00 | 7.00 | 6.00 | 4.00 | 7.00 | 7.00 | 6.00 | 1.00 | -0.95 | 2.00 | -0.07 | 2.00 | 0.00 | 1.00 | 14.00 | -1.48 |
Earnings Before Taxes | 15.8% | 48.00 | 41.00 | 64.00 | 33.00 | 34.00 | 41.00 | 23.00 | 23.00 | 29.00 | 27.00 | 38.00 | 14.00 | 5.00 | -6.74 | 7.00 | -1.50 | 6.00 | 1.00 | 2.00 | 61.00 | -3.63 |
EBT Margin | 3.3% | 0.27* | 0.27* | 0.28* | 0.24* | 0.23* | 0.23* | 0.21* | 0.25* | 0.24* | 0.19* | 0.12* | 0.05* | - | - | - | - | - | - | - | - | - |
Net Income | 19.4% | 43.00 | 36.00 | 49.00 | 26.00 | 26.00 | 34.00 | 16.00 | 17.00 | 24.00 | 20.00 | 30.00 | 8.00 | 5.00 | -6.27 | 4.00 | -0.19 | 4.00 | -1.03 | 1.00 | 48.00 | 1.00 |
Net Income Margin | 7.2% | 0.23* | 0.21* | 0.22* | 0.19* | 0.18* | 0.18* | 0.16* | 0.19* | 0.18* | 0.14* | 0.09* | 0.03* | - | - | - | - | - | - | - | - | - |
Free Cashflow | 222.4% | 46.00 | 14.00 | 54.00 | 46.00 | 31.00 | 9.00 | 15.00 | -3.15 | 45.00 | 34.00 | -4.65 | 26.00 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | 4.1% | 1,574 | 1,513 | 1,545 | 1,378 | 774 | 742 | 727 | 724 | 716 | 672 | 652 | 666 | 646 | 631 | 614 | 600 | 573 | 587 | 586 | 601 | 545 |
Current Assets | 13.4% | 555 | 490 | 543 | 385 | 408 | 378 | 384 | 377 | 364 | 318 | 304 | 311 | 300 | 280 | 277 | 267 | 247 | 255 | 269 | 284 | 230 |
Cash Equivalents | 39.6% | 201 | 144 | 267 | 149 | 177 | 156 | 157 | 166 | 173 | 127 | 107 | 125 | 102 | 95.00 | 90.00 | 89.00 | 57.00 | 76.00 | 87.00 | 122 | 81.00 |
Inventory | 9.1% | 115 | 106 | 110 | 105 | 104 | 104 | 103 | 99.00 | 95.00 | 93.00 | 100 | 98.00 | 97.00 | 97.00 | 109 | 105 | 108 | 111 | 110 | 99.00 | 79.00 |
Net PPE | 2.0% | 289 | 283 | 281 | 279 | 243 | 238 | 233 | 238 | 243 | 244 | 243 | 253 | 253 | 260 | 246 | 238 | 231 | 234 | 222 | 220 | 215 |
Liabilities | 3.3% | 902 | 873 | 949 | 789 | 225 | 213 | 222 | 224 | 237 | 226 | 222 | 199 | 195 | 183 | 163 | 158 | 149 | 159 | 152 | 169 | 164 |
Current Liabilities | 13.2% | 255 | 225 | 258 | 251 | 106 | 95.00 | 102 | 104 | 114 | 104 | 98.00 | 125 | 127 | 112 | 97.00 | 93.00 | 83.00 | 90.00 | 87.00 | 101 | 112 |
Long Term Debt | 0.8% | 594 | 590 | 638 | 488 | 73.00 | 73.00 | 74.00 | 74.00 | 74.00 | 75.00 | 76.00 | 30.00 | 32.00 | 34.00 | 33.00 | 35.00 | 36.00 | 39.00 | 38.00 | 40.00 | 31.00 |
Shareholder's Equity | 5.2% | 672 | 639 | 595 | 589 | 549 | 529 | 505 | 499 | 480 | 446 | 430 | 467 | 451 | 449 | 451 | 442 | 423 | 428 | 434 | 432 | 380 |
Retained Earnings | 10.5% | 452 | 409 | 373 | 324 | 298 | 272 | 238 | 222 | 205 | 180 | 161 | 131 | 123 | 118 | 124 | 120 | 120 | 116 | 117 | 116 | 68.00 |
Additional Paid-In Capital | -2.1% | 476 | 486 | 478 | 471 | 457 | 455 | 449 | 443 | 433 | 422 | 413 | 427 | 414 | 410 | 404 | 397 | 371 | 367 | 362 | 355 | 349 |
Shares Outstanding | 1.6% | 49.00 | 48.00 | 48.00 | 49.00 | 48.00 | 48.00 | 49.00 | 49.00 | 48.00 | 48.00 | 48.00 | 48.00 | - | - | - | - | - | - | - | - | - |
Minority Interest | - | - | - | - | - | - | - | - | - | - | - | - | 45.00 | 45.00 | 46.00 | 46.00 | 45.00 | 46.00 | 46.00 | 44.00 | 44.00 | 45.00 |
Float | - | - | - | - | 1,487 | - | - | - | 885 | - | - | - | 482 | - | - | - | 567 | - | - | - | 638 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | 131.7% | 55,291 | 23,864 | 64,334 | 54,923 | 40,382 | 15,226 | 20,375 | 2,815 | 50,765 | 40,441 | 2,569 | 32,159 | 22,825 | 16,893 | 8,807 | 30,089 | 1,477 | 5,652 | -12,003 | 51,723 | -3,610 |
Share Based Compensation | 59.2% | 7,360 | 4,622 | 4,644 | 4,865 | 6,111 | 4,304 | 4,299 | 4,235 | 5,022 | 3,850 | 3,919 | 6,084 | 4,834 | 4,333 | 4,370 | 6,513 | 5,282 | 4,295 | 4,294 | 4,032 | 4,674 |
Cashflow From Investing | 114.8% | 15,237 | -103,049 | -31,152 | -508,582 | -6,333 | -229 | -15,258 | -8,180 | -9,110 | -11,954 | -3,769 | -4,254 | -8,695 | -12,176 | -5,451 | -10,066 | -8,722 | -7,352 | -18,622 | -9,669 | -14,884 |
Cashflow From Financing | 71.2% | -13,579 | -47,083 | 86,613 | 428,111 | -13,548 | -16,162 | -13,931 | -994 | 4,648 | -8,696 | -16,492 | -5,191 | -6,639 | -227 | -3,026 | 12,456 | -11,449 | -10,382 | -3,888 | -742 | 11,229 |
Buy Backs | - | - | - | 50,001 | 128 | 8,015 | 18,069 | 14,494 | 6,117 | 1,229 | 13,436 | 6,093 | 5,561 | 3,783 | 3,390 | 4,329 | 5,756 | 10,950 | 13,777 | 4,426 | 1,073 | 3,015 |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Net Revenues: | ||
Total net revenues | $ 171,836 | $ 140,022 |
Cost of revenues | 81,736 | 66,182 |
Gross profit | 90,100 | 73,840 |
Operating expenses: | ||
Selling, distribution, and marketing | 9,371 | 7,109 |
General and administrative | 15,676 | 13,483 |
Research and development | 17,043 | 19,815 |
Total operating expenses | 42,090 | 40,407 |
Income from operations | 48,010 | 33,433 |
Non-operating income (expenses): | ||
Interest income | 2,556 | 924 |
Interest expense | (8,611) | (398) |
Other income (expenses), net | 5,921 | (390) |
Total non-operating income (expenses), net | (134) | 136 |
Income before income taxes | 47,876 | 33,569 |
Income tax provision | 4,126 | 6,752 |
Income before equity in losses of unconsolidated affiliate | 43,750 | 26,817 |
Equity in losses of unconsolidated affiliates | (573) | (785) |
Net income attributable to Amphastar Pharmaceuticals, Inc. | 43,177 | 26,032 |
Net income attributable to Amphastar Pharmaceuticals, Inc. | $ 43,177 | $ 26,032 |
Net income per share | ||
Basic (in Dollars per share) | $ 0.90 | $ 0.54 |
Diluted (in Dollars per share) | $ 0.81 | $ 0.50 |
Weighted-average shares used to compute net income per shares | ||
Basic (in Shares) | 48,212 | 48,000 |
Diluted (in Shares) | 53,013 | 51,970 |
Product revenues, net | ||
Net Revenues: | ||
Total net revenues | $ 157,629 | $ 140,022 |
Other revenues | ||
Net Revenues: | ||
Total net revenues | $ 14,207 |
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 201,148 | $ 144,296 |
Restricted cash | 235 | 235 |
Short-term investments | 88,407 | 112,510 |
Restricted short-term investments | 2,200 | 2,200 |
Accounts receivable, net | 138,114 | 114,943 |
Inventories | 115,494 | 105,833 |
Income tax refunds and deposits | 784 | 526 |
Prepaid expenses and other assets | 8,696 | 9,057 |
Total current assets | 555,078 | 489,600 |
Property, plant, and equipment, net | 288,523 | 282,746 |
Finance lease right-of-use assets | 516 | 564 |
Operating lease right-of-use assets | 31,352 | 32,333 |
Investment in unconsolidated affiliate | 527 | |
Goodwill and intangible assets, net | 607,064 | 613,295 |
Long-term investments | 15,163 | 14,685 |
Other assets | 23,369 | 25,910 |
Deferred tax assets | 53,252 | 53,252 |
Total assets | 1,574,317 | 1,512,912 |
Current liabilities: | ||
Accounts payable and accrued liabilities | 116,697 | 93,366 |
Accrued payments for BAQSIMI | 128,245 | 126,090 |
Income taxes payable | 5,857 | 1,609 |
Current portion of long-term debt | 428 | 436 |
Current portion of operating lease liabilities | 3,942 | 3,906 |
Total current liabilities | 255,169 | 225,407 |
Long-term reserve for income tax liabilities | 6,066 | 6,066 |
Long-term debt, net of current portion and unamortized debt issuance costs | 594,006 | 589,579 |
Long-term operating lease liabilities, net of current portion | 28,739 | 29,721 |
Other long-term liabilities | 17,981 | 22,718 |
Total liabilities | 901,961 | 873,491 |
Commitments and Contingencies | ||
Stockholders' equity: | ||
Preferred stock: par value $0.0001; 20,000,000 shares authorized; no shares issued and outstanding | ||
Common stock: par value $0.0001; 300,000,000 shares authorized; 60,160,459 and 48,841,343 shares issued and outstanding as of March 31, 2024 and 59,390,194 and 48,068,881 shares issued and outstanding as of December 31, 2023, respectively | 6 | 6 |
Additional paid-in capital | 476,072 | 486,056 |
Retained earnings | 452,445 | 409,268 |
Accumulated other comprehensive loss | (8,769) | (8,478) |
Treasury stock | (247,398) | (247,431) |
Total equity | 672,356 | 639,421 |
Total liabilities and stockholders' equity | $ 1,574,317 | $ 1,512,912 |
 | Dr. Yongfeng Zhang Ph.D. |
---|---|
 | amphastar.com |
 | Pharmaceuticals |
 | 1615 |